×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
LON:PXS

Provexis (PXS) Share Forecast, Price & News

GBX 0.92
0.00 (0.00%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
0.75
1
50-Day Range
0.75
1.04
52-Week Range
0.70
1.15
Volume
16.02 million shs
Average Volume
1.01 million shs
Market Capitalization
£20.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive PXS News and Ratings via Email

Sign-up to receive the latest news and ratings for Provexis and its competitors with MarketBeat's FREE daily newsletter.

About Provexis

Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Personal Products
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
2
Year Founded
N/A

Sales & Book Value

Annual Sales
£479.45 thousand
Book Value
GBX 0.10 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
2,210,822,000
Free Float
N/A
Market Cap
£20.45 million
Optionable
Not Optionable

Company Calendar

Last Earnings
9/30/2020
Today
5/28/2022

MarketRank

Overall MarketRank

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Provexis (LON:PXS) Frequently Asked Questions

How were Provexis' earnings last quarter?

Provexis plc (LON:PXS) released its earnings results on Wednesday, September, 30th. The company reported ($0.02) earnings per share (EPS) for the quarter.
View Provexis' earnings history
.

Who are Provexis' key executives?
Provexis' management team includes the following people:
  • Mr. Ian Ford BA (Hons) ACA, CEO, CFO, Company Sec. & Exec. Director (Age 56, Pay $130.21k)
  • Dr. Niamh Ann O'Kennedy B.Sc., BSc, M.Sc., MSc, Ph.D., Chief Scientific Officer, Member of Scientific Advisory Board & Exec. Director (Age 48, Pay $84.04k)
  • Prof. Asim K. Duttaroy BS MS Ph.D., DSc FICN, Consultant & Member of Scientific Advisory Board
Who are some of Provexis' key competitors?
What other stocks do shareholders of Provexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provexis investors own include Taylor Wimpey (TW), ValiRx (VAL), Sirius Minerals (SXX), Lloyds Banking Group (LLOY) and easyJet (EZJ).

What is Provexis' stock symbol?

Provexis trades on the London Stock Exchange (LON) under the ticker symbol "PXS."

How do I buy shares of Provexis?

Shares of PXS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Provexis' stock price today?

One share of PXS stock can currently be purchased for approximately GBX 0.93.

How much money does Provexis make?

Provexis has a market capitalization of £20.45 million and generates £479.45 thousand in revenue each year.

How many employees does Provexis have?

Provexis employs 2 workers across the globe.

What is Provexis' official website?

The official website for Provexis is www.provexis.org.

How can I contact Provexis?

Provexis' mailing address is Prospect HSE, 58 Queens Road, READING, RG1 4RP, United Kingdom. The company can be reached via phone at +44-1753-861777.

This page was last updated on 5/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.